(117) have shown that in preclinical mouse studies, CTLA-4 blockade combined with anti-PD1 provided greater tumor clearance of TSC-associated tumors than anti-PD1 treatment alone. The gene discussed is CTLA4; the disease is tuberous sclerosis.